Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Indian J Med Microbiol
;
2012 Jul-Sept; 30(3): 350-351
Artigo
em Inglês
| IMSEAR
| ID: sea-143983
ABSTRACT
Recently, doripenem has been approved for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP). The E-test was performed to determine the MICs of doripenem and meropenem in 203 endotracheal aspirate isolates that consisted of 140 Acinetobacter calcoaceticus-Acinetobacter baumannii complexes and 63 Pseudomonas aeruginosa. Doripenem showed minimum concentration necessary for inhibition of 50% (MIC 50 ) of P. aeruginosa isolates at 0.38 mg/L which is several times (84.2 times) lower than the corresponding MIC 50 value of >32 mg/L for meropenem. The MIC 50 and MIC 90 were similar for both the drugs against A. baumannii. Thus, P. aeruginosa was consistently more susceptible than the A. baumannii.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Pseudomonas aeruginosa
/
Infecções por Pseudomonas
/
Infecções por Acinetobacter
/
Humanos
/
Testes de Sensibilidade Microbiana
/
Carbapenêmicos
/
Tienamicinas
/
Acinetobacter calcoaceticus
/
Acinetobacter baumannii
/
Pneumonia Associada à Ventilação Mecânica
Idioma:
Inglês
Revista:
Indian J Med Microbiol
Assunto da revista:
Microbiology
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS